Royal Fund Management LLC Purchases 3,825 Shares of Eli Lilly and Company (NYSE:LLY)

Royal Fund Management LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 118.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,056 shares of the company’s stock after buying an additional 3,825 shares during the period. Royal Fund Management LLC’s holdings in Eli Lilly and Company were worth $6,251,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Twelve Points Wealth Management LLC increased its holdings in Eli Lilly and Company by 1.4% in the second quarter. Twelve Points Wealth Management LLC now owns 811 shares of the company’s stock worth $734,000 after purchasing an additional 11 shares in the last quarter. Verum Partners LLC lifted its position in shares of Eli Lilly and Company by 1.5% during the 2nd quarter. Verum Partners LLC now owns 731 shares of the company’s stock valued at $662,000 after acquiring an additional 11 shares during the period. Beaird Harris Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 2.2% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 512 shares of the company’s stock valued at $464,000 after acquiring an additional 11 shares during the period. Acorn Creek Capital LLC boosted its stake in Eli Lilly and Company by 1.3% during the second quarter. Acorn Creek Capital LLC now owns 927 shares of the company’s stock worth $840,000 after acquiring an additional 12 shares in the last quarter. Finally, Thompson Davis & CO. Inc. grew its holdings in Eli Lilly and Company by 0.7% in the second quarter. Thompson Davis & CO. Inc. now owns 1,687 shares of the company’s stock worth $1,527,000 after purchasing an additional 12 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Barclays upped their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Jefferies Financial Group raised their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,025.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 3rd. BMO Capital Markets increased their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Bank of America boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Trading Up 0.2 %

Shares of NYSE:LLY traded up $1.72 during trading on Wednesday, reaching $915.44. 204,306 shares of the company traded hands, compared to its average volume of 3,011,750. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53. The firm has a market capitalization of $870.04 billion, a price-to-earnings ratio of 134.57, a P/E/G ratio of 2.78 and a beta of 0.42. The business’s fifty day moving average is $904.41 and its 200-day moving average is $850.31.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.